Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00377 | 35111690 | Front Cell Infect Microbiol | Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients. | 2022 | Details |
| A00378 | 35111461 | Cureus | Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD). | 2021 | Details |
| A00380 | 35109946 | Nutr Res Rev | NAFLD and vitamin D: Evidence for intersection of microRNA-regulated pathways. | 2021 | Details |
| A00387 | 35107488 | Arq Bras Cir Dig | OBESITY AND SEVERE STEATOSIS: THE IMPORTANCE OF BIOCHEMICAL EXAMS AND SCORES. | 2022 | Details |
| A00396 | 35102112 | Eur J Gastroenterol Hepatol | Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease. | 2022 | Details |
| A00397 | 35101634 | Clin Gastroenterol Hepatol | Myosteatosis, but not Sarcopenia, Predisposes NAFLD Subjects to Early Steatohepatitis and Fibrosis Progression. | 2022 | Details |
| A00402 | 35100462 | Diabet Med | An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care. | 2022 | Details |
| A00405 | 35098442 | Hepatol Int | Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review. | 2022 | Details |
| A00408 | 35096879 | Front Med (Lausanne) | Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter. | 2022 | Details |
| A00409 | 35096868 | Front Med (Lausanne) | MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. | 2022 | Details |
| A00414 | 35093339 | Life Sci | Endothelial group IVA phospholipase A2 promotes hepatic fibrosis with sinusoidal capillarization in the early stage of non-alcoholic steatohepatitis in mice. | 2022 | Details |
| A00415 | 35093101 | J Transl Med | Single-cell transcriptomic analysis reveals a novel cell state and switching genes during hepatic stellate cell activation in vitro. | 2022 | Details |
| A00423 | 35089884 | Chin Med J (Engl) | Non-invasive tests of non-alcoholic fatty liver disease. | 2022 | Details |
| A00425 | 35089208 | Medicine (Baltimore) | Association between liver stiffness measurement by transient elastography and chronic kidney disease. | 2022 | Details |
| A00426 | 35089193 | Medicine (Baltimore) | Serum cadmium is associated with hepatic steatosis and fibrosis: Korean national health and nutrition examination survey data IV-VII. | 2022 | Details |
| A00435 | 35085294 | PLoS One | Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease. | 2022 | Details |
| A00436 | 35085026 | Metab Syndr Relat Disord | Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00439 | 35083765 | Hepatology | Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome. | 2022 | Details |
| A00441 | 35083257 | Front Med (Lausanne) | Hepatic Unsaturated Fatty Acids Are Linked to Lower Degree of Fibrosis in Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00442 | 35082753 | Front Endocrinol (Lausanne) | Triglyceride-Rich Lipoproteins and Glycoprotein A and B Assessed by 1H-NMR in Metabolic-Associated Fatty Liver Disease. | 2022 | Details |
| A00443 | 35081304 | Diabetes Metab J | Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00444 | 35080508 | Clin Transl Gastroenterol | Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study. | 2022 | Details |
| A00455 | 35075592 | Hepatol Int | Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. | 2022 | Details |
| A00457 | 35075185 | Sci Rep | MAFLD progression contributes to altered thalamus metabolism and brain structure. | 2022 | Details |
| A00461 | 35072021 | JHEP Rep | Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. | 2021 | Details |
| A00464 | 35070304 | Mol Clin Oncol | Serine palmitoyltransferase long chain subunit 3 is associated with hepatocellular carcinoma in patients with NAFLD. | 2021 | Details |
| A00466 | 35070015 | World J Hepatol | Determination of "indeterminate score" measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia. | 2021 | Details |
| A00473 | 35068797 | J Clin Exp Hepatol | Magnetic Resonance Elastography for the Clinical Risk Assessment of Fibrosis, Cirrhosis, and Portal Hypertension in Patients With NAFLD. | 2021 | Details |
| A00474 | 35068796 | J Clin Exp Hepatol | A Current Understanding of Bile Acids in Chronic Liver Disease. | 2021 | Details |
| A00475 | 35068786 | J Clin Exp Hepatol | Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study. | 2021 | Details |
| A00480 | 35067116 | Ethn Health | Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S. | 2022 | Details |
| A00481 | 35066992 | Liver Int | The burden of NAFLD in type 2 diabetic subjects from the general population: A Nationwide population-based follow-up study (NASHCO). | 2022 | Details |
| A00491 | 35063601 | J Hepatol | Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. | 2022 | Details |
| A00494 | 35062050 | Biomed Pharmacother | CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver. | 2022 | Details |
| A00505 | 35058605 | Eur J Clin Nutr | Effects of a low free sugar diet on the management of nonalcoholic fatty liver disease: a randomized clinical trial. | 2022 | Details |
| A00507 | 35058515 | Sci Rep | Low heart rate variability from 10-s electrocardiograms is associated with development of non-alcoholic fatty liver disease. | 2022 | Details |
| A00508 | 35058147 | Eur J Intern Med | Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis. | 2022 | Details |
| A00510 | 35057565 | Nutrients | Switching to Regular Diet Partially Resolves Liver Fibrosis Induced by High-Fat, High-Cholesterol Diet in Mice. | 2022 | Details |
| A00513 | 35055797 | Int J Environ Res Public Health | Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study. | 2022 | Details |
| A00514 | 35055407 | J Pers Med | Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00518 | 35054837 | Int J Mol Sci | The Potential Role of Cellular Senescence in Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00524 | 35053404 | Cells | Role of Mitochondrial Cytochrome P450 2E1 in Healthy and Diseased Liver. | 2022 | Details |
| A00525 | 35053253 | Biomolecules | Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. | 2022 | Details |
| A00526 | 35053205 | Biomolecules | Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. | 2021 | Details |
| A00527 | 35053008 | Biology (Basel) | The Snoring Index Identifies Risk of Non-Alcoholic Fatty Liver Disease in Patients with Obstructive Sleep Apnea Syndrome. | 2021 | Details |
| A00529 | 35052872 | Biomedicines | Detailed Molecular Mechanisms Involved in Drug-Induced Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: An Update. | 2022 | Details |
| A00535 | 35052736 | Biomedicines | Differential iNKT and T Cells Activation in Non-Alcoholic Fatty Liver Disease and Drug-Induced Liver Injury. | 2021 | Details |
| A00537 | 35052690 | Biomedicines | Nonalcoholic Fatty Liver Disease (NAFLD): Pathogenesis and Noninvasive Diagnosis. | 2021 | Details |
| A00541 | 35052595 | Antioxidants (Basel) | Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A00545 | 35051649 | Clin Gastroenterol Hepatol | Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. | 2022 | Details |
| A00552 | 35048297 | J Gen Intern Med | The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care. | 2022 | Details |
| A00557 | 35047125 | World J Diabetes | Skeletal muscle loss is associated with diabetes in middle-aged and older Chinese men without non-alcoholic fatty liver disease. | 2021 | Details |
| A00577 | 35042213 | Pathobiology | Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: Immunohistochemical Assessment of Markers of Cancer Cell Metabolism. | 2022 | Details |
| A00578 | 35041626 | Am J Gastroenterol | Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00580 | 35040788 | Turk J Gastroenterol | Association Between Neutrophil-to-Lymphocyte Ratio with Inflammatory Activity and Fibrosis in Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00581 | 35040549 | Hepatol Res | 2-Step PLT16-AST44 method: Simplified liver fibrosis detection system in patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A00585 | 35040007 | Mol Biol Rep | High-fat diet intake ameliorates the expression of hedgehog signaling pathway in adult rat liver. | 2022 | Details |
| A00590 | 35038159 | J Cell Commun Signal | Targeting CCN2 protects against progressive non-alcoholic steatohepatitis in a preclinical model induced by high-fat feeding and type 2 diabetes. | 2022 | Details |
| A00591 | 35036892 | Metabol Open | Noninvasive assessment of fibrosis among patients with nonalcoholic fatty liver disease [NAFLD]. | 2022 | Details |
| A00594 | 35035690 | Am J Transl Res | Bile acid metabolism and liver fibrosis following treatment with bifid triple viable capsules in nonalcoholic fatty liver disease. | 2021 | Details |
| A00598 | 35035359 | Front Physiol | Exercise Alleviates the Apolipoprotein A5-Toll-Like Receptor 4 Axis Impairment in Mice With High-Fat Diet-Induced Non-alcoholic Steatohepatitis. | 2021 | Details |
| A00602 | 35034553 | J Med Econ | Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease. | 2022 | Details |
| A00609 | 35030323 | Lancet Gastroenterol Hepatol | Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. | 2022 | Details |
| A00610 | 35030194 | PLoS One | Mechanisms of liver injury in high fat sugar diet fed mice that lack hepatocyte X-box binding protein 1. | 2022 | Details |
| A00616 | 35027111 | J Am Coll Cardiol | Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. | 2022 | Details |
| A00620 | 35024739 | Rom J Morphol Embryol | Systemic and adipose tissue inflammation in NASH: correlations with histopathological aspects. | 2022 | Details |
| A00621 | 35024735 | Rom J Morphol Embryol | Triglyceride and glucose index: a useful tool for non-alcoholic liver disease assessed by liver biopsy in patients with metabolic syndrome? | 2022 | Details |
| A00626 | 35023936 | Diabetes Metab Syndr Obes | Diagnostic Value of Neutrophil to Lymphocyte Ratio in Non-Alcoholic Fatty Liver Disease Evaluated Using Transient Elastography (TE) with Controlled Attenuated Parameter (CAP). | 2022 | Details |
| A00635 | 35020496 | Metab Syndr Relat Disord | Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients. | 2022 | Details |
| A00651 | 35014161 | Diabetes Obes Metab | The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment. | 2022 | Details |
| A00652 | 35014156 | Diabetes Obes Metab | Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study. | 2022 | Details |
| A00653 | 35014145 | Diabetes Obes Metab | Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). | 2022 | Details |
| A00657 | 35013082 | AIDS | Prevalence of non-alcoholic fatty liver disease using non-invasive techniques among children, adolescents, and youths living with HIV. | 2022 | Details |
| A00661 | 35011625 | Cells | The Nuclear Receptor PXR in Chronic Liver Disease. | 2021 | Details |
| A00666 | 35010924 | Nutrients | Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model. | 2021 | Details |
| A00669 | 35008925 | Int J Mol Sci | Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future. | 2022 | Details |
| A00670 | 35008852 | Int J Mol Sci | Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases. | 2021 | Details |
| A00671 | 35008682 | Int J Mol Sci | Emerging Roles of Calcium Signaling in the Development of Non-Alcoholic Fatty Liver Disease. | 2021 | Details |
| A00673 | 35007752 | J Biomed Inform | Stratifying individuals into non-alcoholic fatty liver disease risk levels using time series machine learning models. | 2022 | Details |
| A00676 | 35005800 | Aliment Pharmacol Ther | A sequential approach using the age-adjusted fibrosis-4 index and vibration-controlled transient elastography to detect advanced fibrosis in Korean patients with non-alcoholic fatty liver disease. | 2022 | Details |
| A00686 | 35003876 | Biomed Opt Express | Intravital two-photon imaging and quantification of hepatic steatosis and fibrosis in a live small animal model. | 2021 | Details |
| A00687 | 35003513 | Oxid Med Cell Longev | TNF-Like Ligand 1 Aberrance Aggravates Nonalcoholic Steatohepatitis via M1 Macrophage Polarization. | 2021 | Details |
| A00691 | 35002729 | Front Pharmacol | Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease. | 2021 | Details |
| A00693 | 35001345 | J Physiol Biochem | Vaspin attenuates steatosis-induced fibrosis via GRP78 receptor by targeting AMPK signaling pathway. | 2022 | Details |
| A00695 | 35000120 | Clin J Gastroenterol | The impact of emricasan on chronic liver diseases: current data. | 2022 | Details |
| A00698 | 34998993 | Clin Gastroenterol Hepatol | Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00701 | 34998036 | Int Immunopharmacol | Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. | 2022 | Details |
| A00702 | 34997649 | J Clin Lab Anal | The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. | 2022 | Details |
| A00703 | 34997159 | Sci Rep | Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease. | 2022 | Details |
| A00704 | 34996457 | Lipids Health Dis | NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study. | 2022 | Details |
| A00709 | 34993389 | Curr Dev Nutr | Considerations When Choosing High-Fat, High-Fructose, and High-Cholesterol Diets to Induce Experimental Nonalcoholic Fatty Liver Disease in Laboratory Animal Models. | 2021 | Details |
| A00711 | 34992694 | Dis Markers | Nonalcoholic Fatty Liver Disease-Associated Liver Fibrosis Is Linked with the Severity of Coronary Artery Disease Mediated by Systemic Inflammation. | 2021 | Details |
| A00716 | 34992072 | BMJ Open Gastroenterol | Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD. | 2022 | Details |
| A00721 | 34990037 | Hepatology | Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. | 2022 | Details |
| A00722 | 34988994 | Aliment Pharmacol Ther | Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis. | 2022 | Details |
| A00723 | 34988895 | Obes Surg | Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States. | 2022 | Details |
| A00725 | 34988225 | Biomed Res Int | Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis. | 2021 | Details |
| A00727 | 34987607 | Therap Adv Gastroenterol | Application of artificial intelligence in non-alcoholic fatty liver disease and liver fibrosis: a systematic review and meta-analysis. | 2021 | Details |
| A00747 | 34981313 | Dig Dis Sci | Bariatric Surgery in NAFLD. | 2022 | Details |
| A00756 | 34978351 | Aliment Pharmacol Ther | Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods. | 2022 | Details |